

Supporting Information for

Original article

Inactivation of TFEB and NF- κ B by marchantin M alleviates the chemotherapy-driven pro-tumorigenic senescent secretion

Huanmin Niu^{a,†}, Lilin Qian^{a,†}, Bin Sun^b, Wenjian Liu^a, Fang Wang^a, Qian Wang^a, Xiaotian Ji^a, Yanhai Luo^a, Effat Un Nesa^c, Hongxiang Lou^b, Huiqing Yuan^{a,*}

^a*Institute of Medical Sciences/Department of Biochemistry and Molecular Biology, the Second Hospital of Shandong University, Jinan 250033, China*

^b*Key Laboratory of Natural Products & Chemical Biology, Ministry of Education, Department of Natural Products Chemistry, School of Pharmaceutical Sciences, Shandong University, Jinan 250012, China.*

^c*Department of Radiation Oncology, Qilu Hospital of Shandong University, Jinan 250012, China*

Received 1 July 2019; received in revised form 4 August 2019; accepted 19 August 2019

*Corresponding Author. Tel.: +86 531 85875027.

E-mail: lyuanhq@sdu.edu.cn (Huiqing Yuan).

†These authors made equal contributions to this work.

Table S1 The primers used in this experiment.

Name		Primer
Human <i>IL-1α</i>	Forward	GGTTGAGTTTAAGCCAATCCA
	Reverse	TGCTGACCTAGGCTTGATGA
Human <i>IL-1β</i>	Forward	GTCGGAGATTCGTAGCTGGAT
	Reverse	CTCGCCAGTGAAATGATGGCT
Human <i>IL-6</i>	Forward	TCAATGAGGAGACTTGCCTGG
	Reverse	GGCTGGCATTGTGGTTGG
Human <i>IL-8</i>	Forward	AGACAGCAGAGCACACAAGC
	Reverse	ATGGTTCCTTCCGGTGGT
Human <i>TNF-α</i>	Forward	CAGCCTCTTCTCCTTCCTGAT
	Reverse	GCCAGAGGGCTGATTAGAGA
Human <i>IFN-γ</i>	Forward	TCGGTAACTGACTTGAATGTCCA
	Reverse	TCGCTTCCCTGTTTTAGCTGC
Human <i>IL-4</i>	Forward	CAGACATCTTTGCTGCCTCC
	Reverse	AGCTGCTTGTGCCTGTGG
Human <i>IL-5</i>	Forward	ATCTTTCAGGGAATAGGCACA
	Reverse	TTGCAGGTAGTCTAGGAATTGGTT
Human <i>IL-10</i>	Forward	AAGCTGAGAACCAAGACCCAGACA
	Reverse	AAAGGCATTCTTCACCTGCTCCAC
Human <i>IL-13</i>	Forward	CACTGGGCCTCATGGCGCTT
	Reverse	TGGCACTGCAGCCTGACACG




Figure S1 Marchantin M induces senescence in other drug-resistant cells. (A) Survival rates of PC3 and PC3/Doc cells treated with doxorubicin (Doxo), docetaxel (Doc), and Mar-M. (B) Morphology and proliferation changes for PC3 and PC3/Doc cells under Doxo prolonged treatment. Scale bar: 100 μm . (C) SA- β -gal expression in RM1, RM1/Doc, H460, H460/RT, EC109, EC109/CDDP cells treated with 1 $\mu\text{mol/L}$ Mar-M for 1 day. Scale bar: 100 μm . (D) Western blot analysis of the expression of Rb and p-Rb in PC3/Doc cells treatment with Mar-M for 5 days.